Exchange Traded Concepts LLC Has $8.97 Million Stock Holdings in Bio-Rad Laboratories, Inc. $BIO

Exchange Traded Concepts LLC raised its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 37.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 29,592 shares of the medical research company’s stock after acquiring an additional 8,012 shares during the period. Exchange Traded Concepts LLC owned about 0.11% of Bio-Rad Laboratories worth $8,966,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC raised its holdings in shares of Bio-Rad Laboratories by 195.6% in the fourth quarter. SG Americas Securities LLC now owns 18,958 shares of the medical research company’s stock valued at $5,744,000 after purchasing an additional 12,544 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Bio-Rad Laboratories by 23.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,211 shares of the medical research company’s stock worth $670,000 after purchasing an additional 415 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Bio-Rad Laboratories by 8.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 1,168 shares of the medical research company’s stock worth $380,000 after purchasing an additional 95 shares during the last quarter. RK Asset Management LLC grew its position in Bio-Rad Laboratories by 0.5% in the fourth quarter. RK Asset Management LLC now owns 14,573 shares of the medical research company’s stock valued at $4,415,000 after purchasing an additional 71 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Bio-Rad Laboratories by 14.0% in the fourth quarter. GAMMA Investing LLC now owns 1,125 shares of the medical research company’s stock valued at $341,000 after purchasing an additional 138 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 0.1%

NYSE BIO opened at $265.16 on Monday. The company has a market cap of $7.16 billion, a PE ratio of 9.50 and a beta of 1.18. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $343.12. The stock has a 50 day moving average of $281.43 and a 200-day moving average of $298.69.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The firm had revenue of $693.20 million for the quarter, compared to analyst estimates of $694.64 million. During the same quarter in the previous year, the firm posted $2.90 earnings per share. Bio-Rad Laboratories’s quarterly revenue was up 3.9% on a year-over-year basis. On average, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on BIO shares. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $358.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.